Krystal Biotech Posts $127.3 Million VYJUVEK Revenue, Authorizes Buyback
Third-quarter product revenue grew 30% year over year as Krystal reported net income of $63.1 million and approved a repurchase program.
Makkler Newsroom · Nov 2, 03:21 PM · 1 min read